Literature DB >> 2723538

Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase.

U P Steinbrecher1, P H Pritchard.   

Abstract

Degradation of phosphatidylcholine to lysophosphatidylcholine occurs during oxidative modification of low density lipoproteins (LDL). In this study, we have shown that this phospholipid hydrolysis is brought about by an LDL-associated phospholipase A2 that can hydrolyze oxidized but not intact LDL phosphatidylcholine. The chemical nature of the oxidized phospholipids that can act as substrates for this enzyme was not fully characterized, but we hypothesized that the specificity of the enzyme for oxidized LDL phosphatidylcholine might be explained by fragmentation of polyunsaturated sn-2 fatty acyl groups in LDL phosphatidylcholine during oxidation. To facilitate characterization of this enzyme, we therefore selected a fluorescent phosphatidylcholine substrate that had a short-chain, polar residue in the sn-2 position: 1-palmitoyl 2-(6-[7-nitrobenzoxadiazolyl]amino) caproyl phosphatidylcholine, (C6NBD PC). This substrate was efficiently hydrolyzed by LDL, but the dodecanoyl analogue of C6NBD PC, which differed only in that a 12-carbon rather than a 6-carbon acyl derivative was present in the sn-2 position, was not hydrolyzed. The phospholipase activity was heat-stable, calcium-independent, and was inhibited by the serine esterase inhibitors phenylmethylsulfonyl-fluoride and diisopropylfluorophosphate, but was resistant to p-bromophenacylbromide and dithiobisnitrobenzoic acid. The phospholipid hydrolysis could not be attributed to the action of lecithin:cholesterol acyltransferase or lipoprotein lipase. Nearly all of the activity in EDTA-anticoagulated normal plasma was physically associated with apoB-containing lipoproteins, but this apoprotein was not essential as enzyme activity was present in plasma from abetalipoproteinemic patients. These properties are very similar to those recently reported for human plasma platelet-activating factor (PAF) acetylhydrolase. In the present study, we found that acylhydrolase activity against C6NBD PC, PAF, and oxidized phosphatidylcholine copurfied through gel filtration and ion-exchange chromatography. Substrate competition was demonstrated between C6NBD PC, PAF, and oxidized 2-arachidonyl phosphatidylcholine, suggesting that a single enzyme was active against all three substrates. The enzyme had an apparent molecular weight of 40,000-45,000 by high pressure gel exclusion chromatography. Inhibition of this activity with disopropyfluorophosphate prior to oxidative modification of LDL prevented phospholipid hydrolysis but did not affect the production of thiobarbituric acid reactive compounds or the change in electrophoretic mobility. In addition, this inhibition of phospholipase did not prevent the rapid degradati

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2723538

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  39 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Determination of phospholipase activity of PAF acetylhydrolase.

Authors:  Diana M Stafforini; Thomas M McIntyre
Journal:  Free Radic Biol Med       Date:  2012-05-29       Impact factor: 7.376

3.  Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages.

Authors:  Konstantinos P Markakis; Maria K Koropouli; Stavroula Grammenou-Savvoglou; Ewoud C van Winden; Andromaxi A Dimitriou; Constantinos A Demopoulos; Alexandros D Tselepis; Eleni E Kotsifaki
Journal:  J Lipid Res       Date:  2010-03-23       Impact factor: 5.922

4.  Phospholipase A2 activity of low density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100.

Authors:  S Parthasarathy; J Barnett
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein.

Authors:  D C Tsoukatos; T A Liapikos; A D Tselepis; M J Chapman; E Ninio
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

6.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

Authors:  E Nobécourt; S Jacqueminet; B Hansel; S Chantepie; A Grimaldi; M J Chapman; A Kontush
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

7.  Comparative toxicity of oxidatively modified low-density lipoprotein and lysophosphatidylcholine in cultured vascular endothelial cells.

Authors:  M Naito; K Yamada; T Hayashi; K Asai; N Yoshimine; A Iguchi
Journal:  Heart Vessels       Date:  1994       Impact factor: 2.037

8.  Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from healthy habitual cigarette smokers.

Authors:  T Imaizumi; K Satoh; H Yoshida; Y Kawamura; M Hiramoto; M Koyanagi; S Takamatsu; M Takamatsu
Journal:  Heart Vessels       Date:  1990       Impact factor: 2.037

9.  Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.

Authors:  G Ambrosio; A Oriente; C Napoli; G Palumbo; P Chiariello; G Marone; M Condorelli; M Chiariello; M Triggiani
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

10.  A 31P nuclear magnetic resonance investigation of acyl group transfer from phosphatidylcholine to yield lysophosphatidylcholine in human plasma.

Authors:  M H Nouri-Sorkhabi; D R Sullivan; D C Roberts; P W Kuchel
Journal:  Lipids       Date:  1994-03       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.